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ChurgeStrauss syndrome is an uncommon multisystem disorder characterized by asthma, eosinophilia
and vasculitis. We report on a 12-year-old boy with asthma and deterioration of his general condition,
who was eventually diagnosed with an ANCA-negative ChurgeStrauss syndrome. The propositus
included, 50 cases of childhood ChurgeStrauss syndrome have been reported. The patient characteristics
and clinical characteristics of these children are summarized. The respiratory tract is most frequently
involved with pulmonary inﬁltrates, asthma and sinusitis. Early recognition of childhood ChurgeStrauss
syndrome is important as delayed diagnosis can lead to severe organ involvement, and possible fatal
outcome.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
ChurgeStrauss syndrome (CSS), also called allergic gran-
ulomatosis and angiitis, is an uncommon multisystem disorder of
unknown etiology, characterized by necrotizing vasculitis affecting
small to medium-sized vessels (1). Patients usually present with
a history of asthma, allergic rhinitis and prominent peripheral
blood eosinophilia.2
CSS in childhood is rare and the clinical presentation can be
quite diverse. Although CSS is an antineutrophil cytoplasmic anti-
body (ANCA)-associated vasculitis, ANCA in children are only foundtology; ANCA, antineutrophil
; CT, computed tomography;
exhaled nitric oxide; Ig,
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-NC-ND license.in 40% of the cases.3,4 Therefore, diagnosing CSS in children may be
difﬁcult. However, early recognition of the disease is important, as
delayed diagnosis can lead to severe organ involvement, and
sometimes fatal outcome.2
We report on a 12-year-old boy with asthma and deterioration
of his general condition, who was eventually diagnosed with an
ANCA-negative ChurgeStrauss syndrome.
2. Case report
A 12-year-old boy presentedwith a dramatic deterioration of his
general condition, characterized by extreme fatigue, weight loss
(2.6 kg in three weeks), fever, a typical respiratory symptoms and
abdominal pain.
Eleven months earlier, he presented with his ﬁrst acute asthma
exacerbation, which was treated with frequent nebulisation of
ipratropium and salbutamol, and oxygen. Laboratory and pulmo-
nary investigations showed a total immunoglobulin (Ig) E of 228
kU/l. Allergy tests were positive for grass and tree pollen. Spirom-
etry demonstrated a reversible airway obstruction. Fractional
exhaled nitric oxide (FeNO) was increased (38.5 ppb) at a time
Fig. 2. Chest computed tomography (before treatment with prednisone) revealing
bilateral pulmonary inﬁltrates with lower lobe predominance (small arrow), peripheral
consolidations (thick arrow) and some pericardial effusion (interrupted arrow).
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therapy with salmeterol/ﬂuticasone to 5.6 ppb (reference range of
FeNO: low < 5 ppb; normal 5e20 ppb; increased 20e35 ppb;
high > 35 ppb).
During summer holidays abroad, his general condition deteri-
orated progressively. Additional examinations revealed a leukocy-
tosis (26.5  109/L) with nearly 50% eosinophils, whereas the total
IgE increased to 2901 kU/L. One day after return from holidays he
presented at our emergency department with respiratory distress,
and was subsequently hospitalized for further investigations and
therapeutical intervention.
Physical examination revealed cachexia, several skin lesions on
the elbows, back and feet (Fig. 1), and two palpable subcutaneous
nodules on the back. Breathing frequency was 23 per minute,
transcutaneous oxygen saturation was 97%. Auscultation of lungs,
heart and abdomen was normal. There was no hep-
atosplenomegaly. Neurological examination was normal.
White blood cell differentiation and blood smear conﬁrmed
leukocytosis (31.9  109/L) and hypereosinophilia (12.4 109/l, 39%
eosinophils). C-reactive protein and erythrocyte sedimentation rate
were raised (66 mg/L and 64 mm/h, respectively). IgG and E levels
were elevated (27.7 g/L and 2445 kU/l, respectively). Complement
C3 and C4 were normal. Anti-nuclear antibody, anti-streptolysine-
O, anti-DNAse B, p-ANCA, c-ANCA, MPO-ANCA and PR3-ANCAwere
all negative. Rheumatic factor was minimally elevated (22 U/L).
Urinalysis, renal and liver function tests were normal.
Chest radiography and computed tomography (CT) revealed
bilateral inﬁltrates with lower lobe predominance and peripheral
consolidations, as well as some pericardial effusion (Fig. 2). Bron-
choalveolar lavage ﬂuid demonstrated leukocytes of 1.8  109/lL
with 76% eosinophils. Biopsy of the skin lesion showed capillaritis
with ﬁbrin thrombi and eosinophilic inﬂammation. Biopsy of the
subcutaneous nodule showed multinodular basophilic necrosis
with eosinophilic inﬂammation. Both biopsies were suggestive of
eosinophilic vasculitis (Fig. 3a, b).
The diagnosis of pulmonary inﬁltrates with eosinophilia, or
eosinophilic lung disease (ELD) was made, based on eosinophilia in
peripheral blood, pulmonary inﬁltrates, eosinophilia in bron-
choalveolar lavage ﬂuid, and eosinophilia in skin biopsy. ELD can be
classiﬁed according to known and unknown etiology, and miscel-
laneous. Known causes of ELD are mostly infectious, e.g. parasitic
infections or aspergillosus. Because ELD encompass a wide variety
of disorders, broad therapeutical intervention was initially started
with prednisone, ceftriaxone, azithromycin and itraconazole.
Symptoms improved rapidly. Blood eosinophilia disappearedFig. 1. Elevated skin lesions on the feet, compatible with vasculitis.
Fig. 3. (a): Biopsy of the skin lesion, showing dermal eosinophilic inﬁltrate. (b): Biopsy
of subcutaneous nodule, showing multinodular basophilic necrosis (small arrow) with
eosinophilic inﬂammation (thick arrow).
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substantial improvement. This indicated a rapid steroid respon-
siveness. Extensive cultures and serologic tests showed no evidence
of infectious diseases, including negative speciﬁc IgE to Aspergillus.
After 9 days of hospitalization, the child was discharged to
home. He was treated with oral prednisone (2 mg/kg/day) main-
tenance therapy for 10 weeks, and thereafter, the dose was slowly
reduced to 0.3 mg/kg every other day for 26 weeks after diagnosis.
Twenty-eight weeks after diagnosis, the child presented with
progressive coughing and blood eosinophilia (2.75109/L). He was
hospitalized and needed extra oxygen. Symptoms improved rapidly
after increasing prednisone to 1 mg/kg/day and blood eosinophilia
disappeared within one week. Until present, he remained steroid
dependent despite interventions with additional consecutive
immunosuppressive therapy: azathioprine at 50 mg/m2/day for 4
months (discontinued due to increased transaminases);
mycophenolate-mofetil at 1200 mg/m2/day for 2 months; meth-
ylprednisolone 600 mg pulses intravenously during 3 consecutive
days, monthly for 3 months; cyclophosphamide (600 mg/m2,
monthly for 8 months).5 Currently, 24 months after diagnosis, he is
treated with methotrexate (25 mg subcutaneously, once a week),
beclomethasone (1 mg/twice a day nebulized), long-acting bron-
chodilators, and the use of prednisolone is being tapered.
3. Discussion
We present a boy with asthma, prominent eosinophilia and
pulmonary inﬁltrates. Because of the cutaneous involvement and
a history of asthma, ChurgeStrauss syndrome was considered.
The combination of allergic granulomatosis, allergic angiitis and
periarteritis nodosa was described by Churg and Strauss in 1951 as
a clinical syndrome consisting of severe asthma, fever, and hyper-
eosinophilia, in associationwith symptoms of vascular involvement
in various organ systems.1
The exact pathogenesis of CSS is unknown. At least three
potential mechanisms have been implicated: 1) asthma, involving
Th2 lymphocytes; 2) the contribution of ANCA in the development
of vasculitis; and 3) the role of eosinophils.6 Several asthma
medications have been associated with the appearance of CSS. It
has been suggested that improved asthma control by adding
leukotrienemodifying agents and/or inhaled glucocorticoids allows
tapering of the systemic steroid dose, but consequently unmasking
an underlying systemic inﬂammatory process.7
In CSS, three sequential phases are described: 1) the prodromale
phase characterized by allergic rhinitis and asthma; 2) the eosin-
ophilic phase with eosinophilic inﬁltration in multiple organs
especially in the respiratory and gastrointestinal tract; and 3) the
vasculitic phase in which a systemic vasculitis of the small and
medium vessels develops, often with malaise, weight loss, and
fever.8
The American College of Rheumatology (ACR) proposed 6
criteria for the ChurgeStrauss syndrome: asthma, peripheral blood
eosinophilia (more than 10% on differential white blood cell count),
mononeuropathy or polyneuropathy, non-ﬁxed pulmonary inﬁl-
trates, paranasal sinus abnormalities, and extravascular eosino-
philia.9 The presence of 4 or more of these criteria yielded
a sensitivity of 85% and a speciﬁcity of 99.7%.9 Histologically, there
is a typical triad of necrotizing vasculitis, granulomas, and extra-
vascular eosinophilia.2 Our patient met 4 of the 6 criteria for CSS
and had 2 histological signs of CSS (vasculitis, eosinophilia). ANCA
in our patient was negative.
CSS is rare in childhood and the clinical presentation can be
quite diverse. In 2008, Zwerina et al reported 33 cases of CSS in
children. To our knowledge, sixteen other cases have subsequently
been reported.6,10e24 In total, 50 cases of childhood CSS aresummarized: the mean age at presentation was 10 years (range 2e
18 yr) and childhood CSS occurred more frequently in girls than in
boys (22 boys, 28 girls, male-to-female ratio 0.79). The most
frequent clinical characteristics were: pulmonary involvement
(90%, i.e. pulmonary inﬁltrates, wheezing, pleural effusions and
alveloar hemorraghe), asthma (88%), sinusitis (76%), and skin
involvement (73%, i.e. rash, purpura, nodules and ulceration).
Cardiac involvement was seen in 22 of 44 patients (50%), most often
pericardial effusions and cardiomyopathy, but also myocarditis,
valve regurgitation and cardiac thrombosis. Neurological involve-
ment was seen in 21 of 42 patients (50%), i.e. mononeuritis multi-
plex, polyneuropathy, hemichorea, bilateral optic neuropathy and
loss of vision. In declining order of frequency, gastrointestinal (45%,
i.e. abdominal pain, diarrhea, ulceration, abdominal mass and
hepatic venous outﬂow obstruction) and musculoskeletal (45%, i.e.
myalgia and arthalgia) symptoms were reported. Renal involve-
ment was seen less frequent (21%, i.e. proteinuria, hematuria,
glomerulonephritis and IgA-nefropathy). Results of ANCA testing
were reported in 26 patients, of whom 6 were positive (23%).
Miscellaneous symptoms are: lymphadenopathy, testicular pain,
thymic mass, orbital pseudotumor, deep venous thrombosis and
Raynaud phenomenon.
Initially, all patients received corticosteroids, usually predni-
sone 1e2 mg/kg/d. Corticosteroids and additional immunosup-
pressive therapy were initially given in 10 out of 47 patients (21%).
Disease relapse was reported in 23 out of 46 patients (50%) within
a half to 26 months. At relapse, 8 patients received corticosteroids
monotherapy (35%) and 15 patients received additional immuno-
suppressive therapy (65%), usually cyclophosphamide, and in one
case mycophenolate-mofetil. The mortality of CSS is substantial, 10
out of 47 patients (21%) died after a disease duration of 2e26
months. Two patients died within short time when therapy was
refused or stopped. Reported causes of death are: respiratory
insufﬁciency (n ¼ 1), pulmonary abscess and sepsis (n ¼ 1), cardiac
failure (n ¼ 3), cardiac arrest and severe myocarditis (n ¼ 1),
intestinal perforation (n ¼ 2), intestinal perforation and septicae-
mia (n ¼ 1), and gastrointestinal inﬂammation with necrosis and
sepsis (n ¼ 1).
Zwerina et al compared CSS in childhood with CSS in adults.2
Asthma is frequent in all patients.2 Other organ involvement is
different among children and adults.2 Pulmonary inﬁltrates and
cardiac disease are seen more frequently in children.2 Peripheral
nerve and musculoskeletal symptoms are seen more frequently in
adults.2 ANCA are found in about 1/3 of adult and in 1/4 of
childhood patients with CSS, respectively.2 The outcome in
childhood seems to be worse.2 Reasons for these differences
remains elusive.2
In conclusion, we present a 12-year-old boy with an ANCA-
negative ChurgeStrauss syndrome. The clinical presentation of
childhood CSS can be diverse, with involvement of different organ
systems. The respiratory tract is most frequently involved, with
pulmonary inﬁltrates, asthma symptoms and sinusitis. Early
recognition of childhood CSS is important as delayed diagnosis can
lead to severe organ involvement and a fatal outcome.
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Educational aims
- ChurgeStrauss syndrome is a multisystem disorder of
unknown etiology characterized by asthma, eosinophilia and
vasculitis.
- In childhood, ChurgeStrauss syndrome is rare and the clinical
presentation diverse.
- In childrenwith ChurgeStrauss syndrome, the respiratory tract
is most frequently involved with pulmonary inﬁltrates, asthma
and sinusitis.
- Early recognition of childhood ChurgeStrauss syndrome is
important as delayed diagnosis can lead to severe organ
involvement and fatal outcome.Educational questions
1. ChurgeStrauss syndrome is an antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitis. ANCA in children are
found in the majority of the cases.
Answer: False. Although ChurgeStrauss syndrome is an ANCA-
associated vasculitis, ANCA are only found in 40% of the cases.
2. The American College of Rheumatology developed six criteria
for ChurgeStrauss syndrome: asthma, peripheral blood
eosinophilia, mononeuropathy or polyneuropathy, non-ﬁxed
pulmonary inﬁltrates, and extravascular eosinophils. The
sixth criterium is paranasal sinus abnormalities.
Answer: True. The presence of four or more of these six criteria
yielded a sensitivity of 85% and a speciﬁcity of 99.7%.
3. Typical histology in ChurgeStrauss syndrome is characterized
by non-necrotizing vasculitis and extravascular eosinophilia.
Answer: False. Typically a triad is found of necrotizing vascu-
litis, granulomas and extravascular eosinophilia.
4. ChurgeStrauss syndrome is a multisystem disorder. In chil-
dren, neurological and gastrointestinal symptoms are the most
frequent extra-pulmonary manifestations.
Answer: False. In decliningorderof frequency, extra-pulmonary
manifestations in children are: skin involvement (73%), cardiac
involvement (50%), neurological (50%), gastrointestinal (45%),
musculoskeletal (45%) and renal involvement (21%).
5. In general, the treatment of ChurgeStrauss syndrome is
primarily based on corticosteroids and sometimes combined
with additional immunosuppressive therapy. During child-
hood, disease relapse is rare.Answer: False. Disease relapse was reported in 50% of the
children, and occurred within 0.5e26 months of time.
6. The mortality of childhood ChurgeStrauss syndrome is less
than 5%.
Answer: False. The mortality of ChurgeStrauss syndrome is
substantial: 21% of the children (10 out of 47) died after
a disease duration of 2e26 months.
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